Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced the initiation of clinical imaging assessing the use of a potential marker for delivery of MM-398 (irinotecan liposome injection), …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced data for MM-398 (irinotecan liposome injection), also known as ”nal-IRI,” in a Phase 1 investigator-sponsored study at the University …
Recently, various healthcare executives have taken part in insider buying activity for the stocks of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Opko Health Inc. (NYSE:OPK), …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced the initiation of a randomized, double-blinded, placebo-controlled Phase 2 clinical trial of MM-141, a bispecific antibody targeting IGF-1R …
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) and Baxter International Inc.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Baxter International Inc. (NYSE:BAX) jointly announced that Merrimack has completed the rolling submission of the New Drug Application …
In a research report issued today, Cantor analyst Daniel Brims reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, following …
In a research report issued today, Cantor analyst Daniel Brims reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a price target of …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a …
